Physician profile
Christopher Joseph Thomas
NPI 1427579283
$476.07
in general payments reported to CMS, 2019-2025
10 companies · $92.79 in 2025
The $92.79 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2023: $155 · 2024: $116 · 2025: $92.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $321 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $321.02 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $124.86 | 2023 | Qutenza |
| Astrazeneca Pharmaceuticals LP | $116.19 | 2024 | Lokelma |
| Mannkind Corporation | $78.00 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $44.89 | 2019 | |
| Abbvie INC. | $29.68 | 2023 | Vraylar |
| Advanced Respiratory, INC | $28.42 | 2019 | |
| Lilly USA, LLC | $14.79 | 2025 | Zepbound, Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $14.71 | 2019 | |
| Merck Sharp & Dohme LLC | $12.38 | 2019 | |
| Astellas Pharma US INC | $12.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.